$3.82
+0.23 (+6.41%)
Open$3.63
Previous Close$3.59
Day High$3.85
Day Low$3.61
52W High$9.94
52W Low$3.57
Volume—
Avg Volume1.62M
Market Cap220.27M
P/E Ratio—
EPS$-4.63
SectorBiotechnology
Analyst Ratings
Strong Buy
11 analysts
Price Target
+304.5% upside
Current
$3.82
$3.82
Target
$15.45
$15.45
$11.33
$15.45 avg
$18.37
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 212.56M | 224.44M | 122.09M |
| Net Income | -216,864,356 | -206,079,527 | 12.67M |
| Profit Margin | -102.0% | -96.9% | 10.4% |
| EBITDA | -141,799,715 | -142,233,902 | 21.61M |
| Free Cash Flow | — | — | 20.08M |
| Rev Growth | -5.3% | -5.3% | +22.8% |
| Debt/Equity | 0.02 | 0.02 | 0.48 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |